Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Spruce Biosciences, Inc. (OTC: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2025 and provided corporate updates.
'With no FDA-approved treatments currently available to treat MPS IIIB, TA-ERT has the potential to be a groundbreaking advancement for patients and families impacted by this devastating disease,' said Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer of Spruce. 'Across the landscape, this is an incredibly important and exciting time for patients and families affected by neuropathic MPS diseases. Looking ahead, we remain focused on pursuing accelerated approval of TA-ERT and filing the BLA in the first half of 2026. We also plan to initiate a confirmatory study prior to potential accelerated approval of TA-ERT and enable expanded access programs to ensure that patients have access to therapy.'
Corporate Updates
TA-ERT for the Treatment of MPS IIIB. Spruce entered into an Asset Purchase Agreement under which the company acquired an exclusive worldwide license agreement for TA-ERT and other enzyme replacement therapy products. TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. In March 2024, in a Type C meeting with the U.S. Food and Drug Administration (FDA), the FDA confirmed that HS-NRE is deemed to be a surrogate biomarker reasonably likely to predict clinical benefit and could serve as a basis for accelerated approval. The FDA also confirmed that the completed clinical and non-clinical studies of TA-ERT were sufficient for a BLA submission and provided guidance around key design elements of a confirmatory trial, which must be initiated prior to potential accelerated approval of TA-ERT. TA-ERT has received Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation in the U.S. and EU. Spruce intends to submit the BLA of TA-ERT for the treatment of MPS IIIB in the first half of 2026.
Tildacerfont and Cortibon for the Treatment of Major Depressive Disorder (MDD). Spruce entered into a license, development and option agreement (the 'HMNC Agreement') with HMNC Holding GmbH ('HMNC'). Under the terms of the HMNC Agreement, HMNC will fund and conduct a Phase 2 proof-of-concept study of tildacerfont, a potent and highly selective, oral, small-molecule antagonist of the CRF 1 receptor, in patients with MDD who will be screened using Cortibon, HMNC's proprietary genetic test. HMNC has initiated the Phase 2 TAMARIND study, which will explore the efficacy of 400mg twice-daily tildacerfont versus placebo in improving depressive symptoms in MDD patients. Topline results from TAMARIND are anticipated in the first half of 2026.
First Quarter 2025 Financial Results
Cash and Cash Equivalents: Cash and cash equivalents as of March 31, 2025 were $25.6 million. Cash and cash equivalents are expected to allow the company to fund its current operating plan through the end of 2025.
Research and Development (R&D) Expenses: R&D expenses for the three months ended March 31, 2025 were $10.8 million compared to $10.3 million for the same period in 2024. R&D expenses for the three months ended March 31, 2025 include $5.7 million in costs related to the acquisition of SPR202, an anti-corticotrophin releasing hormone monoclonal antibody for the treatment of congenital adrenal hyperplasia.
General and Administrative (G&A) Expenses: G&A expenses for the three months ended March 31, 2025 were $3.7 million compared to $4.3 million for the same period in 2024, primarily driven by a decrease in stock-based compensation expense.
Total Operating Expenses: Total operating expenses for the three months ended March 31, 2025 were $14.5 million compared to $14.6 million for the same period in 2024. Operating expenses include non-cash stock-based compensation expenses of $0.5 million for the three months ended March 31, 2025 compared to $1.6 million for the same period in 2024.
Net Loss: Net loss for the three months ended March 31, 2025 was $14.0 million compared to $11.6 million for the same period in 2024.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the ability to seek accelerated approval of TA-ERT for MPS IIIB based on existing clinical data; the anticipated timing and conduct of Spruce's confirmatory trial for TA-ERT; the timing and likelihood of regulatory filings and approvals for TA-ERT, including the anticipated BLA Submission of TA-ERT for MPS IIIB in the first half of 2026; Spruce's expectation that topline results from the TAMARIND study will be available in the first half of 2026; and Spruce's intended focus on serious diseases with significant unmet medical need and clear biology, are forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as 'anticipate', 'will', 'potential', 'intend', 'expect' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Spruce's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Spruce's business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Spruce's filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Spruce undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
March 31,
2025
2024
ASSETS
Current assets:
Cash and cash equivalents
$
25,615
$
38,753
Prepaid expenses
2,899
3,177
Other current assets
2,062
2,276
Total current assets
30,576
44,206
Right-of-use assets
869
934
Other assets
204
69
Total assets
$
31,649
$
45,209
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$
1,879
$
1,295
Accrued expenses and other current liabilities
12,442
12,329
Term loan, current portion
1,345
1,622
Total current liabilities
15,666
15,246
Lease liabilities, net of current portion
659
736
Term loan, net of current portion
—
124
Other liabilities
—
282
Total liabilities
16,325
16,388
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued or outstanding as of March 31, 2025 and December 31, 2024
—
—
Common stock, $0.0001 par value; 200,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 42,231,285 shares issued and outstanding as of March 31, 2025 and December 31, 2024
4
4
Additional paid-in capital
279,629
279,085
Accumulated deficit
(264,309
)
(250,268
)
Total stockholders' equity
15,324
28,821
Total liabilities and stockholders' equity
$
31,649
$
45,209
Expand
SPRUCE BIOSCIENCES, INC.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(unaudited)
(in thousands, except share and per share amounts)
Three Months Ended March 31,
2025
2024
Collaboration revenue
$
—
$
2,002
Operating expenses:
Research and development
10,837
10,317
General and administrative
3,655
4,318
Total operating expenses
14,492
14,635
Loss from operations
(14,492
)
(12,633
)
Interest expense
(36
)
(97
)
Interest and other income, net
487
1,105
Net loss and comprehensive loss
(14,041
)
(11,625
)
Net loss per share, basic and diluted
$
(0.32
)
$
(0.28
)
Weighted-average shares of common stock outstanding, basic and diluted
43,944,946
41,096,231
Expand
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
16 minutes ago
- Time Business News
Your Guide to Botox and Lip Fillers in El Segundo
If you've ever looked in the mirror and thought, 'Hmm, maybe just a little boost,' you're not alone. Botox and lip fillers have become incredibly popular, especially among people who want a natural, refreshed look without surgery. In El Segundo, more and more locals are discovering the power of subtle cosmetic treatments. Whether it's smoothing out a few lines or adding volume to your lips, the right provider can make all the difference. That's why so many people are turning to this clinic, known for its careful work and personalized results. Let's clear up the myths first. Botox isn't about 'freezing your face.' It's a simple treatment that relaxes the muscles under your skin, mostly in areas where fine lines form from repeated facial expressions like frowning or smiling. It's FDA-approved and has been used safely for years. Most people use Botox to reduce lines around the forehead, between the eyebrows, and around the eyes (those 'crow's feet'). Treatments take just 10–15 minutes, and you can go back to your day right after. The results appear within a few days and can last three to four months. It's not permanent, which means you can always adjust how much or how little you want in future visits. Lip fillers are perfect if you want fuller, smoother, or more balanced lips. Most fillers today use hyaluronic acid—a substance your body already makes. It adds volume and shape in a way that feels soft and natural. You don't need to go for an over-the-top look. In fact, many people use fillers to correct asymmetry or just add a touch of definition. The procedure usually takes under 30 minutes, and results are immediate. Swelling may happen for a day or two, but it's usually mild. With proper care, lip fillers can last from 6 months to a full year. Most adults are good candidates, but your provider will always check your medical history to make sure it's safe for you. These treatments are great for: ● People see early signs of aging ● Anyone wanting subtle improvements ● Those preparing for events like weddings or reunions ● People who want to boost their confidence What's important is going to a qualified injector. You don't want just anyone putting a needle in your face. A licensed expert knows how to enhance your natural features, not change them. If it's your first time, don't worry. Most clinics make the process easy and comfortable. Here's how it usually works: 1. Consultation: You'll talk about what you want, ask questions, and get expert advice. 2. Prep: The provider may mark the treatment areas and apply a numbing cream if needed. 3. Injection: It takes just minutes to do the actual injections. 4. Aftercare: You'll get tips on how to avoid swelling or bruising, like skipping alcohol or heavy workouts for a day. You may be surprised by how quick and simple the whole thing is. Myth 1: Botox and fillers are only for older people. Truth: Many younger people use these treatments to prevent lines before they form. Myth 2: You'll look fake or 'done.' Truth: When done right, the results look natural and fresh—not frozen or overfilled. Myth 3: It's super painful. Truth: Most people say it feels like a tiny pinch or quick sting. Plus, numbing options help. Don't just look at price—look at experience and reputation. Read reviews. Check before-and-after photos. Ask how many years they've been doing this work. A great provider listens, explains clearly, and never pressures you into getting more than you need. Also, make sure the place is clean, licensed, and uses approved products. You deserve the best care for your face. Getting Botox or lip fillers or any form of cosmetic help isn't about changing who you are. It's about feeling confident in your skin and doing something for you . Whether you're after smoother skin or fuller lips, a little enhancement can go a long way when done right. Ready to explore your options in El Segundo? A good first step is booking a consultation and asking questions. You'll be amazed at how small changes can lead to a big boost in self-esteem. TIME BUSINESS NEWS
The Hill
13 hours ago
- The Hill
Food and Drug Administration staff cuts may hinder US biomedical innovation
President Trump has rightly emphasized restoring America's economic and strategic independence — from reshoring pharmaceutical production to cutting regulatory red tape. But not all reforms are created equal. Recent restructuring efforts at the Food and Drug Administration may have been well-intentioned, but they risk undermining the very innovation and domestic capacity the president seeks to promote. In March, Health and Human Services Secretary Robert F. Kennedy Jr. announced a sweeping reorganization of the agency, which in part included the elimination of 3,500 full-time employees at the Food and Drug Administration — many of them senior scientific staff and experienced regulators who served as institutional pillars across drug review divisions. While we all support government efficiency and the secretary's efforts to create a gold-standard regulatory agency, the loss of this institutional memory risks hobbling the expedited pathways that small biotech firms rely on to deliver therapies for rare and life-threatening diseases. Unfortunately, the impact of these cuts is not theoretical. The Wall Street Journal has reported that some biotech firms have had to delay or cancel clinical trials due to lack of timely Food and Drug Administration guidance. One California biotech firm facing unpredictable delays has even turned to European regulators to move forward with a clinical trial — effectively offshoring American capital, investment and jobs. Others have reported receiving conflicting and confusing feedback from inexperienced FDA staff or no response at all on time-sensitive requests. But such issues don't just affect companies; they hurt patients, too. Innovation in gene therapies, cancer immunotherapies, and treatments for rare diseases depend on regulatory clarity and speed. Without senior staff to help clarify agency positions, decisions are either delayed or driven by less-experienced personnel unfamiliar with long-standing scientific standards. It's no surprise then that over 200 biotech CEOs, patient advocates and investors — many of them strong supporters of FDA modernization — have expressed their concerns in a letter to Senate Health, Education, Labor and Pensions Committee Chairman Bill Cassidy (R-La.). As a former member of Congress who sat on the Appropriations subcommittee overseeing the FDA, I have long supported targeted reforms to make the agency more nimble and responsive. But there is a fine line between streamlining operations and cutting the institutional capacity necessary to do the job. Removing experienced drug reviewers before an adequate backup plan can be put into place not only jeopardizes U.S. safety standards but also undermines our competitive edge. This matter is not merely a domestic problem; it's a global race. Since 2014, the number of biomedical drugs under development in China has grown twelvefold. Meanwhile, innovation in the U.S. has remained relatively flat. If trends continue, China could match or surpass the U.S. in biomedical innovation within the decade. We have seen this movie before — in semiconductors, in telecommunications, in clean energy. We cannot afford to let biotech go the same way. The Trump administration's tariff policy was designed to bring pharmaceutical manufacturing back to U.S. shores. But how can we expect capital to stay in the U.S. if our regulatory infrastructure cannot deliver? Delays and unpredictability at the FDA don't just slow down science — they push investors to look elsewhere. Even the user fee system — critical to funding timely drug reviews and a source of government revenue — has been impacted by the reduction in force. Staff who oversaw the reauthorization of the Prescription Drug User Fee Act have been laid off, raising questions about whether the agency will even be able to continue to collect user fees and whether these government cuts will actually end up costing taxpayers in the long run. Of course, Kennedy has long been a vocal advocate for health reform. His Make America Healthy Again agenda's focus on combatting chronic diseases and enhancing nutritional standards deserves attention. His focus for such reform is where his background and passion can lead to meaningful improvements. But when it comes to regulating complex biologics and therapeutics, we must be careful about taking actions that could inadvertently stymie scientific progress. President Trump's vision for American self-reliance will only succeed if it's built on a foundation of regulatory competence and stability. Swift actions should therefore be taken to restore the FDA's core functions, rehire critical staff and unfreeze the hiring of roles essential to America's leadership in biomedical science. The stakes — for patients, for innovation and for national security — are simply too high to ignore. John T. Doolittle is a former member of Congress who served on the Agriculture, Rural Development, FDA, and Related Agencies subcommittee of the Committee on Appropriations.
The Hill
14 hours ago
- The Hill
Thanks to imported drugs, America has lost control of its medicine cabinet
America is facing a growing crisis in its medical system — not from a lack of talent or innovation, but from a breakdown in the control, safety and supply of essential medicines. Our growing reliance on imports is now driving serious drug shortages, destabilizing supply chains and increasingly making medications unsafe. At the root of it is a hard truth: We no longer have control of the medicines we depend on every day. In 2002, America manufactured 83.7 percent of the pharmaceuticals it consumed. By 2024, that number had dropped to just 37.1 percent. Meanwhile, the U.S. pharmaceutical trade deficit has soared, reaching a record $118.3 billion in 2024. We didn't just outsource manufacturing — we outsourced the sovereignty and safety of our health care system. This means that nearly two-thirds of America's pharmaceutical supplies are now imported. Most critical medications, such as generic drugs, now come from China and India. China controls 80 to 90 percent of the global supply of active pharmaceutical ingredients — the chemical building blocks of modern medicine. Even drugs labeled 'Made in the USA' often chemically originate in China. And India, which produces about half of America's finished generic drugs, relies on China for up to 80 percent of its active pharmaceutical not a supply chain — it's a ticking time something goes wrong, American patients suffer. In 2023, the Food and Drug Administration shut down a single Indian plant responsible for 50 percent of the U.S. supply of cisplatin, a critical chemotherapy drug, after uncovering a 'cascade of failure' in safety practices and shredded documents soaked in acid. With no domestic backup, patients nationwide had their treatments delayed. That wasn't a fluke. 40 percent of U.S. generic drugs have only one FDA-approved manufacturer. Because of that single chokepoint, when one factory fails, the whole system can crack. We are now seeing widespread drug shortages across the medical system. Hospital pharmacists report an average of 301 critical drug shortages at any given time. And 85 percent say these shortages are moderately or critically affecting care. Doctors often lack crucial medicines such as antibiotics, sedatives and cancer drugs. These aren't obscure drugs. They're foundational medicines. But America no longer makes them. Even when imported drugs do arrive, they're not always safe. A 2025 study found that Indian generics are 54 percent more likely to cause serious side effects than their U.S.-made counterparts. Indian factory violations have also been tied to at least eight U.S. patient deaths. China's record is equally disturbing. In 2008, dozens of Americans died after receiving contaminated heparin from Chinese suppliers. This isn't what the American people want. In a national survey, 85 percent of hospital pharmacists said they would pay more for safer generics. But under today's rules, price overshadows quality. Hospitals have little oversight of drug quality — and foreign producers face few consequences for cutting corners. Even the federal government is flying blind. A 2023 Department of Defense review found that 22 percent of essential military-use drugs had unknown ingredient sourcing. That's a national security April, the Trump administration took a necessary step by launching an investigation into generic pharmaceutical imports that correctly frames the issue as a national security threat. But that recognition alone isn't enough. To address this crisis, Washington should impose targeted tariffs on generic drugs from adversarial nations. It must also rebuild domestic pharmaceutical production through tax credits and long-term contracts. America urgently needs full transparency in drug labeling to disclose where drugs and their ingredients are made. The FDA must step up — with stronger enforcement abroad and a ban on imports from repeat safety violators. And to secure critical ingredients during market disruptions, Washington must pursue a long-term vision that includes a 'strategic pharmaceutical reserve.' This isn't just protectionism. It's a restoration of America's medical security. No nation can call itself sovereign if it can't produce its own medicines, and no patient is safe if their health care depends on quality control in a factory 8,000 miles decades, we were told that offshoring production would make things cheaper, smoother and more efficient. But America can no longer depend on unstable foreign suppliers. It's time to restore our pharmaceutical independence and take back control of our medicine cabinet. Andrew Rechenberg is an economist at the Coalition for a Prosperous America.
